The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.
Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
The company recently raised $8 million and is looking to partner with other firms interested in antigen discovery and diagnostic development.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
SerImmune is developing an immune mapping technology that uses next-generation sequencing to identify how circulating antibodies pair with antigens.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.